Blue Trust’s Roivant Sciences ROIV Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
$11.5K Buy
315
+136
+76% +$4.93K ﹤0.01% 1664
2026
Q2
$6.34K Sell
179
-14
-7% -$414 ﹤0.01% 1982
2026
Q1
$5.35K Sell
193
-223
-54% -$5.73K ﹤0.01% 1976
2025
Q4
$9.03K Buy
+416
New +$8.21K ﹤0.01% 1888
2025
Q3
– Sell
-725
Closed -$8.17K – 2664
2025
Q2
$8.17K Sell
725
-119
-14% -$1.29K ﹤0.01% 1920
2025
Q1
$8.52K Hold
844
– – ﹤0.01% 1964
2024
Q4
$10K Sell
844
-368
-30% -$4.35K ﹤0.01% 1865
2024
Q3
$12.8K Buy
1,212
+123
+11% +$1.4K ﹤0.01% 2106
2024
Q2
$11.5K Buy
+1,089
New +$11.9K ﹤0.01% 1884

Other funds holding ROIV

Blue Trust's ROIV Position: Q3 2026 in Review

Blue Trust increased its Roivant Sciences (ROIV) stake by 76% in Q3 2026, buying an estimated $4.93K and bringing the position to 315 shares worth $11.5K. The position accounts for ﹤0.01% of the portfolio, ranked #1664.

Blue Trust first reported a position in ROIV in Q2 2024 and has held it in 9 quarters since. The position peaked at $12.8K in Q3 2024. 430 funds tracked by Wall St. Rank hold ROIV as of Q3 2026.

  • Blue Trust held 315 shares of Roivant Sciences worth $11.5K as of Q3 2026.
  • Blue Trust bought 136 Roivant Sciences shares in Q3 2026, an estimated $4.93K.
  • Roivant Sciences made up ﹤0.01% of Blue Trust's portfolio in Q3 2026, its #1664 holding.
  • Blue Trust first reported a position in Roivant Sciences in Q2 2024 and has held it in 9 quarters since.
  • Blue Trust's Roivant Sciences position peaked at $12.8K in Q3 2024.
  • 430 funds tracked by Wall St. Rank held Roivant Sciences as of Q3 2026.

Based on Blue Trust's 13F filing for Q3 2026, filed 15 Oct 2026.